PATENTS

Patents

[ Polymeric sustained-release drug formulation ]
3 patent applications filed

  • We have developed and currently operate the proprietary sustained-release drug manufacturing platform, 'LLDDS'.
  • LLDDS dissolves polymers and semaglutide in organic solvents and uses high-pressure spraying to produce 20–100 µm microspheres.
  • The entire process is conducted below 30°C to minimize degradation of peptides, antibodies, proteins, and other sensitive drugs.
3

Patent applications filedPolymeric sustained-release drug formulation

2

Design applications filedDesign registration applications

© 10pharma | Business No. 485-88-03185 | CEO: Youngwoo Ro
Units 701–704, SK V1 Tower, 14 Galmachi-ro 288beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Tel: +82-31-8035-3232

COPYRIGHT(C) TENPHARMA. ALL RIGHT RESERVED